Tengion's Neo-Kidney augment delay dialysis Fails-lack of funding

It is really hard to read these and know that all the HUNDREDS of millions invested in the company OVER A DECADE, (the stock went from $5. to .35 a share) all the good they intended, the great initial results , and success comes down to the cancellation of the study due to bankruptcy.

Press Release | Mon Jan 13, 2014 9:00am EST
Tengion Announces Continued Clinical Progress in Its Two Lead Programs
http://www.reuters.com/article/2014/01/13/idUSnGNXbCz3tX+1d1+GNW20140113

WINSTON-SALEM, N.C., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced continued clinical progress in its two lead programs, the Neo-Kidney Augment and the Neo-Urinary Conduit.

The Neo-Kidney Augment, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease (CKD), was implanted in five CKD patients in 2013 in the ongoing Phase 1 clinical trial in Sweden.

The Neo-Kidney Augment is safe and well tolerated in the five patients implanted to date. The Company now plans to expand enrollment in this trial to 15 patients. The Company also announced the initiation of a Phase 1 clinical trial in the U.S. under an open Investigational New Drug (IND) application for the Neo-Kidney Augment.

Tengion will also complete patient enrollment in the ongoing U.S. Phase 1 clinical trial for its second lead program, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal.

……..read more at the link above

UPDATE 2015: STUDY CLOSED Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease
ClinicalTrials.gov processed this record on May 27, 2015
https://clinicaltrials.gov/ct2/show/NCT01846715

Tengion came back from the brink multiple times before sliding into bankruptcy
Dec 30, 2014, 3:03pm EST Updated Dec 30, 2014, 3:05pm EST

ABOUT: http://www.prnewswire.com/news-releases/tengion-reviews-pipeline-progress-at-first-analyst-and-investor-meeting-strategic--clinical-updates-provided-for-regenerative-medicine-programs-105888873.html